Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
BML-190 (formerly IMMA; LM-4131; BML-190; LM4131; BML190; Indomethacin morpholinylamide), is a potent and selective cannabinoid CB2 receptor inverse agonist with potential anti-inflammatory activity. It exhibits 50-fold selectivity over the CB1 receptor and activates the cannabinoid CB2 receptor with a Ki of 435 nM.
Targets |
CB2 ( Ki = 435 nM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Cell Assay |
For 20 to 24 hours, 293/CB2 cells are labeled with [3H]adenine (1 μCi/mL) in MEM containing 1% FBS. After 30 minutes at 37°C, labeled cells are challenged with 50 μM forskolin and the relevant BML-190, and the accumulation of cAMP is measured. Using transfection reagents, 2 × 105 293/CB2 cells are transiently transfected with 16z44 and/or pcDNA3 for IP assays. In order to produce IP, cells are labeled, challenged with BML-190, and assayed. For every data point, triplicates are run, and each ligand is tested in at least three different trials.
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C23H23CLN2O4
|
|
---|---|---|
Molecular Weight |
426.89
|
|
Exact Mass |
426.13
|
|
Elemental Analysis |
C, 64.71; H, 5.43; Cl, 8.30; N, 6.56; O, 14.99
|
|
CAS # |
2854-32-2
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)N4CCOCC4
|
|
InChi Key |
BJSDNVVWJYDOLK-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C23H23ClN2O4/c1-15-19(14-22(27)25-9-11-30-12-10-25)20-13-18(29-2)7-8-21(20)26(15)23(28)16-3-5-17(24)6-4-16/h3-8,13H,9-12,14H2,1-2H3
|
|
Chemical Name |
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3425 mL | 11.7126 mL | 23.4252 mL | |
5 mM | 0.4685 mL | 2.3425 mL | 4.6850 mL | |
10 mM | 0.2343 mL | 1.1713 mL | 2.3425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Total ion chromatogram (L) and reconstructed ion chromatograms (RICs) for BML-190 and its metabolites. Eur J Pharm Sci . 2010 Sep 11;41(1):163-72. td> |
MS/MS spectrum obtained by collision-induced dissociation of the protonated BML-190 at m/z 427 and its proposed fragmentation pathways. Eur J Pharm Sci . 2010 Sep 11;41(1):163-72. td> |